Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): Experience from the G-PCNSL-SG1 trial

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2374-2380

  Korfel, A ^a   Weller, M ^b,c   Martus, P ^c,d   Roth, P ^b,c   Klasen, H A ^e   Roeth, A ^f   Rauch, M ^g   Hertenstein, B ^h   Fischer, T ⁱ   Hundsberger, T ^j,k   Leithauser M ^l   Birnbaum, T ^m   Kirchen, H ⁿ   Mergenthaler, H G ^o   Schubert, J ^p   Berdel, W ^q   Birkmann, J ^r   Hummel, M ^a   Thiel, E ^a   Fischer, L ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e PIUS HOSPITAL   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g EVANGELISCHES KRANKENHAUS   (Germany)

^h KLINIKUM BREMEN MITTE   (Germany)

ⁱ OTTO VON GUERICKE UNIVERSITY   (Germany)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^l ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ Veterinary Hospital Trier   (Germany)

^o KLINIKUM STUTTGART   (Germany)

^p KLINIKUM MINDEN   (Germany)

^q UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^r Nürnberg University   (Germany)

more..

Author keywords

Cerebrospinal fluid; Meningeal dissemination; Primary CNS lymphoma

Indexed keywords

CYTARABINE; IFOSFAMIDE; METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGEAL METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEOCYTOSIS; POLYMERASE CHAIN REACTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT DURATION; WHOLE BODY RADIATION;

EID: 84865537316     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr627     Document Type: Article

References (30)

1. Balmaceda C, Gaynor JJ, Sun M et al. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol 1995; 38: 202-209.
2. Blay JY, Conroy T, Chevreau C et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998; 16: 864-871.
3. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-3150.
4. O'Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519-526.
5. DeAngelis LM, Seiferheld W, Schold SC et al. Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643-4648.
6. Gleissner B, Siehl J, Korfel A et al. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002; 58: 390-396.
7. Khan RB, Shi W, Thaler HT et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 2002; 58: 175-178.
8. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-272.
9. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H et al. European Organisation for Research and Treatment of Cancer Lymphoma Group. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003; 21: 4483-4488.
10. Korfel A, Martus P, Nowrousian MR et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 2005; 128: 177-183.
11. Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24: 5711-5715.
12. Gavrilovic IT, Hormigo A, Yahalom J et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24: 4570-4574.
13. Fischer L, Martus P, Weller M et al. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology 2008; 71: 1102-1108.
14. Kiewe P, Fischer L, Martus P et al. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis. Cancer 2008; 112: 1812-1820.
15. Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11: 1036-1047.
16. Fischer L, Jahnke K, Martus P et al. The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. Haematologica 2006; 91: 429-430.
17. van Dongen JJ, Langerak AW, Brüggemann M et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
18. Pels H, Schmidt-Wolf IGH, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489-4495.
19. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726-2731.
20. Zimmermann HM. Malignant lymphoma of the central nervous system. Acta Neuropathol (Berl) 1975; (Suppl VI): 69-74.
21. Schaumburg HH, Plank CR, Adams RD. The reticulum cell sarcoma- microglioma group of brain tumours. A consideration of their clinical features and therapy. Brain 1972; 95(2): 199-212.
22. Montesinos-Rongen M, Küppers R, Schlüter D et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 1999; 155: 2077-2086.
23. Thompsett AR, Ellison DW, Stevenson FK, Zhu D. V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity. Blood 1999; 94: 1738-1746.
24. Bromberg JE, Breems DA, Kraan J et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007; 68: 1674-1679.
25. Hegde U, Filie A, Little RF et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005; 105: 496-502.
26. Quijano S, López A, Manuel Sancho J et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009; 27: 1462-1469.
27. Kiewe P, Fischer L, Martus P et al. Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort. Neuro Oncol 2010; 12: 409-417.
28. Ferreri AJ, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-1520.
29. Juergens A, Pels H, Rogowski S et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010; 67: 182-189.
30. Pels H, Juergens A, Glasmacher A et al. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 2009; 91: 299-305.